This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Park-Ohio (PKOH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PKOHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Joby Aviation, Inc. (JOBY) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
JOBYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechnology medical vaccines
Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
by Zacks Equity Research
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
NVSNegative Net Change BMYNegative Net Change JNJNegative Net Change LGNDPositive Net Change
biotechnology biotechs
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
by Zacks Equity Research
PDS Biotech's (PDSB) shares gain as it announces encouraging interim data from the VERSATILE-002 study for treating HPV16-positive cancer patients.
MRKNegative Net Change ADMANegative Net Change ALLOPositive Net Change PDSBNegative Net Change
biotechnology medical oncology-screening
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
by Zacks Equity Research
Apexigen (APGN) surges as Pyxis Oncology offers to acquire it for approximately $16 million.
NVONegative Net Change ADMANegative Net Change PYXSPositive Net Change
biotechnology medical
Immutep (IMMP) Up on Initial Data From Lung Cancer Study
by Zacks Equity Research
Immutep (IMMP) shares surge on encouraging initial data from a triple combination therapy study, INSIGHT-003, for non-small cell lung cancer.
MRKNegative Net Change ADMANegative Net Change IMMPNo Net Change ALLOPositive Net Change
biotechnology medical
Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates
by Zacks Equity Research
Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both companies.
IRWDPositive Net Change SRPTPositive Net Change PTCTPositive Net Change ICPTPositive Net Change VECTPositive Net Change
biotechnology biotechs
Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PHATNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy SmartRent, Inc. (SMRT) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SMRTNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Oncobiologics, Inc. (OTLK) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
OTLKNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data
by Zacks Equity Research
Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.
ADMANegative Net Change ALLOPositive Net Change
biotechnology medical vaccines
Should You Buy Crawford United Corporation (CRAWA) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CRAWAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Weave Communications, Inc. (WEAV) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
WEAVPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
by Zacks Equity Research
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
BMYNegative Net Change NVONegative Net Change LGNDPositive Net Change
biotechnology biotechs
Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%
by Zacks Equity Research
Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.
IRWDPositive Net Change ABBVNegative Net Change ADMANegative Net Change VECTPositive Net Change
biotechnology medical
Should You Buy ViaSat (VSAT) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
VSATNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation
by Zacks Equity Research
Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.
ICPTPositive Net Change VKTXPositive Net Change MDGLPositive Net Change
biotechnology pharmaceuticals
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
by Zacks Equity Research
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
PBYIPositive Net Change ADMANegative Net Change ALLOPositive Net Change
biotechnology medical
Kelly Services (KELYA)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
KELYANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
by Zacks Equity Research
PDS Biotech (PDSB) shares gain as it completes patient enrollment in the second arm of the VERSATILE-002 study for treating HPV16-positive cancer patients.
MRKNegative Net Change HALONegative Net Change ALLOPositive Net Change PDSBNegative Net Change
biotechnology medical
Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now
by Zacks Equity Research
ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.
NVSNegative Net Change RHHBYNegative Net Change IMGNPositive Net Change CTMXPositive Net Change
biotechnology immuno-therapy medical
MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study
by Zacks Equity Research
MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.
HALONegative Net Change ALLOPositive Net Change MNMDPositive Net Change
biotechnology medical
Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment
by Zacks Equity Research
Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.
ICPTPositive Net Change VKTXPositive Net Change MDGLPositive Net Change
biotechnology biotechs